147.80
0.40 (0.27%)
| Penutupan Terdahulu | 147.40 |
| Buka | 146.70 |
| Jumlah Dagangan | 4,728,955 |
| Purata Dagangan (3B) | 7,317,118 |
| Modal Pasaran | 220,754,083,840 |
| Harga / Pendapatan (P/E Ke hadapan) | 128.21 |
| Harga / Jualan (P/S) | 6.54 |
| Harga / Buku (P/B) | 7.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -9.40% |
| Margin Operasi (TTM) | 0.99% |
| EPS Cair (TTM) | -2.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 48.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.49% |
| Nisbah Semasa (MRQ) | 1.96 |
| Aliran Tunai Operasi (OCF TTM) | 212.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -120.68 M |
| Pulangan Atas Aset (ROA TTM) | -3.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | BEIGENE | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.50 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BEIGENE | 221 B | - | - | 7.89 |
| HENLIUS | 30 B | - | 33.10 | 9.20 |
| ASCENTAGE-B | 28 B | - | - | 102.10 |
| INNOCARE | 28 B | - | - | 4.27 |
| EVEREST MED | 19 B | - | - | 5.22 |
| INNOVENT BIO | 141 B | - | - | 10.22 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 4.57% |
| % Dimiliki oleh Institusi | 16.05% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |